Search results
Results from the WOW.Com Content Network
Coronary artery bypass surgery aims to prevent death from coronary artery disease and improve quality of life by relieving angina, the associated feeling of chest pain. [1] The decision to perform surgery is informed by studies of CABG's efficacy in different patient subgroups, based on the lesions' anatomy or how well the heart is functioning.
anthrax (prophylaxis and treatment) Ravagalimab [5] mab: humanized: CD40: Crohn's disease Ravulizumab [26] Ultomiris: mab: humanized: C5: Y: paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome: Refanezumab: mab: humanized: myelin-associated glycoprotein: recovery of motor function after stroke Regavirumab: mab: human ...
Off-pump coronary artery bypass (OPCAB), or beating-heart surgery, is a form of coronary artery bypass graft (CABG) surgery performed without cardiopulmonary bypass (heart-lung machine) as a treatment for coronary heart disease. It was primarily developed in the early 1990s by Dr. Amano Atsushi.
"Results of completion arteriography after minimally invasive off-pump coronary artery bypass". The Annals of Thoracic Surgery. 91 (1): 31– 6, discussion 36–7. doi: 10.1016/j.athoracsur.2010.09.057. PMID 21172481. Hoff SJ (2009). "Off-pump coronary artery bypass: techniques, pitfalls, and results". Seminars in Thoracic and Cardiovascular ...
Minimally invasive direct coronary artery bypass (MIDCAB) is a surgical treatment for coronary heart disease that is a less invasive method of coronary artery bypass surgery (CABG). [1] MIDCAB gains surgical access to the heart with a smaller incision than other types of CABG.
The following are medications commonly prescribed cardiac pharmaceutical agents. The specificity of the following medications is highly variable, and often are not particularly specific to a given class. As such, they are listed as are commonly accepted.
Belumosudil, sold under the brand name Rezurock among others, is a medication used for the treatment of chronic graft versus host disease (cGvHD). [1] [5] [6] It is in the class of drugs known as serine/threonine kinase inhibitors. [6] Specifically, it is an inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II). [7]
Remestemcel, sold under the brand name Ryoncil, is an allogeneic bone marrow-derived mesenchymal stromal cell therapy used for the treatment of graft-versus-host disease. [1] [2] Remestemcel contains mesenchymal stromal cells, which are a type of cell that can have various roles in the body and can differentiate into multiple other types of cells. [3]